Study guide

2.2 Heart Failure & Cardiogenic Shock

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

2.2 Heart Failure & Cardiogenic Shock

Key Takeaways Explain This Topic AI

Acute decompensated heart failure (ADHF) presents with signs of pulmonary congestion (crackles, orthopnoea, paroxysmal nocturnal dyspnoea) and systemic venous overload (elevated JVP, hepatojugular reflux, peripheral oedema, S3 gallop).

Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) exhibits exceptionally high negative predictive value; a level below 300 pg/mL helps rule out acute heart failure (NICE CG187), and below 400 ng/L in an untreated outpatient makes chronic heart failure less likely (NICE NG106).

Emergency acute decompensation management requires sitting the patient upright, reserving supplemental oxygen strictly for hypoxaemic patients (SpO2 <94%), and administering intravenous bolus loop diuretics (furosemide), with IV nitrates reserved for selected patients (myocardial ischaemia, severe hypertension or regurgitant valve disease).

Chronic heart failure with reduced ejection fraction (HFrEF, LVEF ≤40%) mandates early initiation of the 'Fantastic Four' guideline-directed medical therapy: an SGLT2 inhibitor, an ARNI (or ACE inhibitor), a beta-blocker, and a mineralocorticoid receptor antagonist.

Cardiogenic shock is defined by sustained hypotension (systolic BP <90 mmHg), elevated ventricular filling pressures, and signs of end-organ hypoperfusion (oliguria, cool clammy extremities, lactic acidosis), treated with inotropes (dobutamine) and mechanical circulatory support.

Last updated: October 2026

Heart Failure & Cardiogenic Shock

Heart failure is a complex clinical syndrome characterised by structural or functional impairment of ventricular filling or ejection, leading to elevated intracardiac pressures and inadequate cardiac output at rest or during exertion. In the UK, heart failure affects approximately 1 million individuals and accounts for 5% of all emergency hospital admissions. Clinical practice differentiates acute decompensated heart failure (ADHF), chronic heart failure across ejection fraction phenotypes, and catastrophic cardiogenic shock.

  • 1. Classification & Pathophysiology
  • Ejection Fraction Phenotypes

The European Society of Cardiology (ESC) and UK NICE guidelines categorize heart failure according to left ventricular ejection fraction (LVEF) on transthoracic echocardiography:

HFrEF (Heart Failure with Reduced Ejection Fraction): LVEF ≤40%. Characterised by systolic pump failure, progressive left ventricular dilatation, and eccentric remodelling. Most evidence-based prognostic therapies specifically benefit this cohort.

HFmrEF (Heart Failure with Mildly Reduced Ejection Fraction): LVEF 41–49%. Represents a transitional phenotype that frequently benefits from similar therapies to HFrEF.

HFpEF (Heart Failure with Preserved Ejection Fraction): LVEF ≥50% with evidence of spontaneous or provokable elevated LV filling pressures (e.g. elevated natriuretic peptides, diastolic dysfunction on Doppler echo, left atrial enlargement). Common in elderly, hypertensive, and female patients.

Neurohormonal Maladaptation

Myocardial injury (from ischaemia, hypertension, cardiomyopathy, or myocarditis) leads to reduced cardiac output, triggering compensatory neurohormonal pathways:

Sympathetic Nervous System (SNS): Catecholamine release increases heart rate and contractility, but chronically induces myocyte apoptosis, downregulates beta-1 adrenergic receptors, and causes peripheral vasoconstriction.

Renin-Angiotensin-Aldosterone System (RAAS): Renal hypoperfusion triggers renin release from juxtaglomerular cells. Angiotensin II induces potent vasoconstriction and stimulates aldosterone secretion from the adrenal cortex, driving renal sodium and water retention, myocardial fibrosis, and ventricular stiffening.

Natriuretic Peptide Counter-regulation: Ventricular wall stretch stimulates secretion of B-type natriuretic peptide (BNP) and its biologically inactive cleaved byproduct, NT-proBNP. These peptides promote natriuresis, diuresis, and vasodilation, but their effects are ultimately overwhelmed by hyperactive RAAS and sympathetic tone.

  • 2. Acute Decompensated Heart Failure (ADHF)
  • Clinical Presentation

Patients typically present with severe respiratory distress and volume overload:

Left-Sided Congestion (Pulmonary Venous Hypertension): Severe exertional dyspnoea, orthopnoea (breathlessness when lying flat, measured by the number of pillows required), paroxysmal nocturnal dyspnoea (PND; waking gasping for air 1–2 hours after sleep), tachypnoea, cough producing pink frothy sputum in frank pulmonary oedema, and extensive bilateral inspiratory crackles on auscultation (starting at the lung bases and extending upwards).

Right-Sided Congestion (Systemic Venous Overload): Elevated jugular venous pressure (JVP), positive hepatojugular reflux, tender hepatomegaly, bilateral pitting peripheral oedema (pedal, pretibial, or sacral if recumbent), and ascites.

Cardiac Auscultation: S3 gallop rhythm (a low-frequency third heart sound in early diastole caused by rapid passive filling into a stiff, dilated, volume-overloaded ventricle; highly specific for elevated filling pressures), displaced and diffuse apex beat, and functional mitral or tricuspid regurgitation murmurs.

Diagnostic Evaluation

Serum NT-proBNP: The investigation of choice to rule out heart failure. In acute presentations with acute dyspnoea, NT-proBNP <300 pg/mL has an extraordinary negative predictive value (>98%), safely ruling out heart failure. In non-acute (chronic) settings, NICE NG106 states that an NT-proBNP below 400 ng/L (equivalent to pg/mL) in an untreated person makes heart failure less likely (the ESC uses below 125 pg/mL to rule out). An NT-proBNP above 2,000 ng/L needs urgent specialist assessment and transthoracic echocardiography within 2 weeks ; 400–2,000 ng/L needs them within 6 weeks .

Confounding Factors: Natriuretic peptides are elevated by advanced age, female sex, renal impairment, atrial fibrillation, and systemic sepsis. Levels are paradoxically reduced by obesity.

Chest Radiography (The ABCDE Mnemonic):

A — Alveolar Oedema: Perihilar "bat's wing" or "butterfly" dense bilateral opacities.

B — Kerley B Lines: Short (1–2 cm), thin, horizontal peripheral interstitial lines perpendicular to the pleural surface at the costophrenic angles, reflecting distended interlobular lymphatics.

C — Cardiomegaly: Cardiothoracic ratio (CTR) >0.5 on a standard posteroanterior (PA) erect film.

D — Dilated Upper Lobe Vessels: Upper lobe blood diversion (cephalisation), where pulmonary veins in the upper zones equal or exceed lower zone vessel calibre.

E — Pleural Effusions: Blunting of costophrenic angles, typically bilateral or right-sided predominance.

Transthoracic Echocardiography (TTE): Mandatory in all cases to quantify LVEF, measure chamber dimensions, calculate wall thickness, evaluate valvular integrity, and assess pulmonary artery systolic pressure.

3. Acute Management of Pulmonary Oedema

Acute heart failure is an immediate medical emergency. Management follows a structured decongestion protocol:

Positioning: Sit the patient upright in bed with legs dangling over the edge if tolerated, immediately reducing systemic venous return (preload).

Controlled Oxygenation: High-flow oxygen should not be given routinely. Administer supplemental oxygen only if SpO2 <94% (or target 88–92% if at risk of hypercapnic respiratory failure). Unnecessary hyperoxia induces systemic vasoconstriction and worsens coronary perfusion.

Intravenous Loop Diuretics:

Furosemide 40–80 mg IV bolus (or Bumetanide 1–2 mg IV). If the patient is already taking maintenance oral loop diuretics, the initial IV bolus dose should equal 1 to 2.5 times their total daily oral dose.

Assess clinical response and spot urinary sodium at 2 hours and total urine output at 6 hours (target >100–150 mL/hour). If diuresis is inadequate, double the IV furosemide dose or add a thiazide-like diuretic (e.g. oral metolazone or IV chlorothiazide) to achieve synergistic sequential nephron blockade.

Vasodilators (Intravenous Nitrates):

Intravenous glyceryl trinitrate (GTN) or isosorbide dinitrate infusion is not offered routinely in acute heart failure (NICE CG187). It is used in specific circumstances: concomitant myocardial ischaemia, severe hypertension, or regurgitant aortic or mitral valve disease , with close blood pressure monitoring (ESC guidance considers vasodilators when systolic BP is above 110 mmHg).

Titrate starting at 10–20 mcg/min, monitoring blood pressure every 5 minutes. Avoid completely if systolic BP is <90–100 mmHg.

Non-Invasive Ventilation (NIV / CPAP):

Continuous positive airway pressure (CPAP at 5–10 cmH2O) or bilevel positive airway pressure (BiPAP) should be considered promptly if the patient exhibits persistent severe dyspnoea, tachypnoea, hypoxaemia, and respiratory acidosis despite pharmacotherapy. CPAP increases intrathoracic pressure, reduces venous return, decreases LV afterload, and recruits fluid-filled alveoli.

Avoid Routine Opiates: Routine use of intravenous opiates (morphine/diamorphine) is no longer recommended by ESC or NICE guidelines due to proven associations with respiratory depression, increased rates of invasive mechanical ventilation, and worse clinical outcomes. Reserve strictly for selected patients with intractable distress or terminal palliation.

4. Chronic HFrEF: The "Fantastic Four" Guideline-Directed Therapy

In chronic HFrEF (LVEF ≤40%), modern guidelines mandate early, rapid introduction of four foundational drug classes—often termed the "Fantastic Four"—each demonstrating independent, additive reductions in all-cause mortality, cardiovascular death, and heart failure hospitalisation.

Drug Class & Exemplar Agents Primary Mechanism of Action Target Dose & Titration Strategy Clinical Pearls & Monitoring Requirements

1. SGLT2 Inhibitor ; • Dapagliflozin 10 mg OD; • Empagliflozin 10 mg OD Inhibits sodium-glucose cotransporter 2 in renal proximal tubule; promotes osmotic diuresis, reduces preload/afterload, enhances myocardial energetics, attenuates fibrosis. Fixed dose: 10 mg once daily .; No upward dose titration required. Effective regardless of diabetes status. Can be initiated down to eGFR 20–25 mL/min. Risk of euglycaemic DKA and mycotic genital infections. Mild initial eGFR dip (up to 30%) is normal and reversible.

2. ARNI or ACE Inhibitor ; • Sacubitril-Valsartan (ARNI); • Ramipril (ACEi); • Candesartan (ARB) ARNI: Neprilysin inhibitor (blocks degradation of natriuretic peptides, bradykinin, adrenomedullin) + AT1 receptor blocker.; ACEi: Inhibits conversion of angiotensin I to II. ARNI: Start 49/51 mg BD, titrate to target 97/103 mg BD.; Ramipril: Start 1.25–2.5 mg OD, titrate to target 10 mg OD . ARNI is superior to ACEi in reducing mortality. Mandatory Rule: When switching from an ACE inhibitor to an ARNI, a 36-hour washout period is strictly required to prevent catastrophic, fatal angioedema. Monitor U&Es: accept up to 30% rise in creatinine and K+ up to 5.5 mmol/L.

3. Cardioselective Beta-Blocker ; • Bisoprolol; • Carvedilol; • Nebivolol Antagonises chronic adrenergic stimulation; downregulates SNS toxicity; reduces heart rate, improves diastolic filling time, anti-arrhythmic. Bisoprolol: Start low at 1.25 mg OD; double dose every 2–4 weeks to target 10 mg OD . Crucial: Must only be initiated or up-titrated when the patient is clinically stable and euvolaemic ("start low, go slow"). Starting beta-blockers during acute decompensation precipitates cardiogenic shock.

4. MRA ; • Spironolactone; • Eplerenone Aldosterone receptor antagonist; promotes natriuresis, prevents myocardial and vascular interstitial fibrosis and adverse remodelling. Spironolactone: Start 12.5–25 mg OD; titrate to target 50 mg OD .; (Eplerenone if gynaecomastia occurs). Check U&Es at 1, 4, 8, and 12 weeks post-initiation. Discontinue or halve dose if serum potassium exceeds 5.5 mmol/L or creatinine doubles. Contraindicated if baseline K+ >5.0 mmol/L or eGFR <30 mL/min.

Adjunctive & Device Therapies

Loop Diuretics: Furosemide or bumetanide titrated to the lowest effective dose to maintain euvolaemia. Note: Loop diuretics alleviate congestive symptoms but do not confer a mortality benefit.

Ivabradine: Selective sinus node If ("funny" current) inhibitor. Indicated in patients in normal sinus rhythm with resting heart rate ≥70 bpm and LVEF ≤35% despite receiving maximum tolerated target doses of beta-blockers.

Implantable Cardioverter-Defibrillator (ICD): Indicated for primary prevention of sudden cardiac death in patients with symptomatic HFrEF (NYHA class II–III) and LVEF ≤35% despite at least 3 months of optimal guideline-directed medical therapy, provided life expectancy exceeds 1 year.

Cardiac Resynchronisation Therapy (CRT): Biventricular pacing indicated for patients with LVEF ≤35%, NYHA II–IV symptoms despite optimal GDMT, and complete Left Bundle Branch Block (LBBB) with QRS duration ≥130–150 ms in sinus rhythm, to reverse electromechanical dyssynchrony.

5. Cardiogenic Shock

Cardiogenic shock represents the extreme end of the heart failure spectrum, characterised by profound primary cardiac pump failure resulting in critical systemic tissue hypoperfusion.

Diagnostic Criteria

Sustained Hypotension: Systolic BP <90 mmHg for >30 minutes (or mean arterial pressure [MAP] <65 mmHg), or requirement for vasopressors to maintain SBP ≥90 mmHg.

Evidence of End-Organ Hypoperfusion:

Oliguria (urine output <0.5 mL/kg/hour).

Cold, clammy, cyanotic peripheries and delayed capillary refill (>3 seconds).

Altered mental status (lethargy, agitation, encephalopathy).

Hyperlactataemia (serum arterial lactate >2.0 mmol/L) reflecting widespread anaerobic metabolism.

Haemodynamic Profile: Severely reduced cardiac index (<2.2 L/min/m2) in the presence of elevated pulmonary capillary wedge pressure (PCWP >15 mmHg), confirming pump failure rather than hypovolaemic shock.

Management Strategy

Early Revascularisation: The SHOCK trial confirmed that emergent PCI or CABG significantly improves survival when acute myocardial infarction is the underlying cause (~80% of cardiogenic shock cases).

Inotropic Support: Intravenous Dobutamine (beta-1 agonist with mild beta-2 and alpha-1 activity) is first-line to enhance myocardial contractility and stroke volume. Alternative: Milrinone (phosphodiesterase-3 inhibitor, useful if on chronic beta-blockers, but causes peripheral vasodilation).

Vasopressor Support: Noradrenaline (norepinephrine) is the vasopressor of choice when marked hypotension threatens coronary perfusion, titrated to maintain MAP ≥65 mmHg.

Mechanical Circulatory Support (MCS): Early escalation to temporary mechanical assist devices: Intra-Aortic Balloon Pump (IABP), percutaneous microaxial ventricular assist devices (Impella), or Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO) as a bridge to recovery, revascularisation, or heart transplantation.

Loading diagram... Heart Failure Diagnostic and Management Algorithm